Ends At: 20/06/2018
Contact Email: firstname.lastname@example.org
Contact Phone: 7025085201
kindcongress invites you to attend 6th World Congress on Hepatitis and Liver diseases (Hepatitis 2018) to be held in Dublin, Ireland during June 18-20, 2018. The conference highlights the theme “Raising global awareness on screening and prevention of hepatitis”.
Hepatitis 2018 is the best platform with its well organized scientific program to the audience which includes symposiums, workshops, keynote lectures, plenary talks, panel discussions and poster sessions on latest research and technological developments in the arena as well as therapeutic aspects. The conference invites Hepatologists, Gastroenterologists, Virologists, Microbiologists, Pathologists, Oncologists, Toxicologists, Researchers, Students, Young researchers and business delegates across the globe.
The scope of the Conference:
Hepatitis 2018 provides a great platform by gathering eminent professors, Researchers, Students, and delegates to exchange new ideas. The conference will cover a wide range of topics and allow participants to discuss the management of liver diseases. Hepatitis 2018 conference consists of keynote and plenary lectures, special sessions (Workshop and Symposium), Young Researcher Forum and Poster presentations. Best poster presenters will be judged and awarded during the conference. To encourage broad participation from all over the world Conference Series Ltd is offering reduced registration fee for students.
|Abstract submission opens||September 12, 2017|
|Registration opens||September 12, 2017|
|Early bird registration||December 12, 2017|
|On spot registration||June 18, 2018|
Track 1: Hepatitis B
Hepatitis B is a liver infection caused by the Hepatitis B virus (HBV). HBV is transmitted through activities that involve percutaneous or mucosal contact with infectious blood or body fluids. HBV can survive outside the body at least 7 days and still be capable of causing infection. The best way to prevent hepatitis B is by getting the hepatitis B vaccine. The pathogenesis and clinical manifestations of hepatitis B are due to the interaction of the virus and the host immune system, which lead to liver injury and potentially cirrhosis and hepatocellular carcinoma. Patients can have either an acute symptomatic disease or an asymptomatic disease.
Track 2: Hepatitis C
Hepatitis C is a devastating viral disease that generally progresses slowly, meaning patients often remain asymptomatic and unaware they are infected until very serious and often expensive complications emerge as a result of damage to the liver. It is estimated that about half of those infected are not aware that they carry the virus. The recent remarkable advances in treating hepatitis C built on incremental improvements achieved over the previous two decades to transform hepatitis C from a chronic, fatal disease, to an infection that with new and forthcoming treatments, can be potentially cured.
Track 3: Hepatitis A, D & E
Hepatitis A is an acute infection of the liver caused by the hepatitis A virus. Vaccination against hepatitis A is available. Hepatitis D is a liver disease caused by the hepatitis D virus, (also called delta virus) a defective virus that needs the hepatitis B virus to exist. Infection with hepatitis D can be prevented by hepatitis B vaccine. Hepatitis E is an acute illness but does not cause a chronic infection. It is transmitted via the fecal-oral route and can be spread by eating or drinking contaminated food or water.
Track 4: Hepatitis Vaccination
The best way to prevent hepatitis is by getting the hepatitis vaccines. Vaccination is safe and effective and it is recommended for all. Efforts to develop a hepatitis C vaccine started more than 20 years ago, when the hepatitis C virus was identified. The hepatitis C virus is more variable than are the viruses that cause hepatitis A and hepatitis B. Hepatitis C virus occurs in at least six genetically distinct forms with 50 subtypes. A global vaccine would have to protect against all these variants of the virus.
Track 5: Hepatitis Clinical Research Trials
The aim of the clinical research studies is to learn more about the hepatitis C virus, how it replicates, what causes the damage to the liver and what role the immune system plays in the disease. Research in Hepatitis is becoming increasingly important as millions of people are afflicted with hepatitis each year.